<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2104245181
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Arify
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        248.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alrai Pharmaceutical industry Co. (L.L.C)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Arify contains the active substance aripiprazole and belong to a group of medicines called antipsychotics. It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense.</p><p>Arify is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling &quot;high&quot;, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. In adults it also prevents this condition from returning in patients who have responded to the treatment with Arify.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Arify </strong></p><p>&bull; if you are allergic to aripiprazole or to any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Arify<strong>.</strong></p><p>Suicidal thoughts and behaviours have been reported during aripiprazole treatment. Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.</p><p>Before treatment with Arify, tell your doctor if you suffer from</p><p>&bull; high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite and feeling weak) or family history of diabetes</p><p>&bull; fits (seizures) since your doctor may want to monitor you more closely</p><p>&bull; involuntary, irregular muscle movements, especially in the face</p><p>&bull; cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular disease, stroke or &quot;mini&quot; stroke, abnormal blood pressure</p><p>&bull; blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots</p><p>&bull; past experience with excessive gambling</p><p>If you notice you are gaining weight, develop unusual movements, experience somnolence that interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell your doctor.</p><p>If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you or your carer/relative should tell your doctor if you have ever had a stroke or &quot;mini&quot; stroke.</p><p>Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself. Suicidal thoughts and behaviours have been reported during aripiprazole treatment.</p><p>Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever, sweating, altered mental status, or very rapid or irregular heartbeat.</p><p>Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings.</p><p><u>Your doctor may need to adjust or stop your dose.</u></p><p>Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in your ability to move and balance, which may lead to falls. Caution should be taken, particularly if you are an elderly patient or have some debility.</p><p><strong>Children and adolescents</strong></p><p>Do not use this medicine in children and adolescents under 13 years of age. It is not known if it is safe and effective in these patients.</p><p><strong>Other medicines and Arify.</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Blood pressure-lowering medicines: Arify may increase the effect of medicines used to lower the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure under control.</p><p>Taking Arify with some medicines may mean the doctor will need to change your dose of Arify or the other medicines. It is especially important to mention the following to your doctor:</p><p>&bull; medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide)</p><p>&bull; antidepressants or herbal remedy used to treat depression and anxiety (such as fluoxetine, paroxetine, venlafaxine, St. John&#39;s Wort)</p><p>&bull; antifungal medicines (such as ketoconazole, itraconazole)</p><p>&bull; certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)</p><p>&bull; anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)</p><p>&bull; certain antibiotics used to treat tuberculosis (rifabutin, rifampicin)</p><p>These medicines may increase the risk of side effects or reduce the effect of Arify,; if you get any unusual symptom taking any of these medicines together with Arify, you should see your doctor.</p><p>Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain:</p><p>&bull; triptans, tramadol and tryptophan used for conditions including depression, generalised anxiety disorder, obsessive compulsive disorder (OCD) and social phobia as well as migraine and pain</p><p>&bull; selective-serotonin-reuptake-inhibitors (SSRIs) (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety</p><p>&bull; other anti-depressants (such as venlafaxine and tryptophan) used in major depression</p><p>&bull; tricyclic&rsquo;s (such as clomipramine and amitriptyline) used for depressive illness</p><p>&bull; St John&rsquo;s Wort (Hypericum perforatum) used as a herbal remedy for mild depression</p><p>&bull; pain killers (such as tramadol and pethidine) used for pain relief</p><p>&bull; triptans (such as sumatriptan and zolmitripitan) used for treating migraine</p><p>These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Arify, you should see your doctor.</p><p><strong>Arify with food, drink and alcohol:</strong></p><p>This medicine can be taken regardless of meals.</p><p>Alcohol should be avoided.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>The following symptoms may occur in newborn babies, of mothers that have used Arify in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>If you are taking Arify, your doctor will discuss with you whether you should breast-feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding. You should not do both. Talk to your doctor about the best way to feed your baby if you are taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>Dizziness and vision problems may occur during treatment with this medicine (see section 4). This should be considered in cases where full alertness is required, e.g. when driving a car or handling machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>The recommended dose for adults is 15 mg once a day.</strong>&nbsp;However, your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p><strong>Use in children and adolescents</strong></p><p>This medicinal product may be started at a low dose with the oral solution (liquid) form.</p><p>The dose may be gradually increased to&nbsp;<strong>the recommended dose for adolescents of 10 mg</strong><strong> </strong><strong>once a day.&nbsp;</strong>However, your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p>If you have the impression that the effect of Arify is too strong or too weak, talk to your doctor or pharmacist.</p><p><strong>Try to take Arify at the same time each day.</strong>&nbsp;It does not matter whether you take it with or without food. Always take the tablet with water and swallow it whole.</p><p><strong>Even if you feel better,</strong>&nbsp;do not alter or discontinue the daily dose of Arify<strong> </strong>without first consulting your doctor.</p><p><strong>If you take more Arify than you should</strong></p><p>If you realise you have taken more Arify than your doctor has recommended (or if someone else has taken some of your Arify), contact your doctor right away. If you cannot reach your doctor, go to the nearest hospital and take the pack with you.</p><p>Patients who have taken too much aripiprazole have experienced the following symptoms:</p><p>&bull; rapid heartbeat, agitation/aggressiveness, problems with speech.</p><p>&bull; unusual movements (especially of the face or tongue) and reduced level of consciousness.</p><p>Other symptoms may include:</p><p>&bull; acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,</p><p>&bull; muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood pressure, abnormal rhythms of the heart.</p><p>Contact your doctor or hospital immediately if you experience any of the above.</p><p><strong>If you forget to take Arify</strong></p><p>If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.</p><p><strong>If you stop taking Arify</strong></p><p>Do not stop your treatment just because you feel better. It is important that you carry on taking Arify for as long as your doctor has told you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&bull; diabetes mellitus,</p><p>&bull; difficulty sleeping,</p><p>&bull; feeling anxious,</p><p>&bull; feeling restless and unable to keep still, difficulty sitting still,</p><p>&bull; akathisia (an uncomfortable feeling of inner restlessness and a compelling need to move constantly),</p><p>&bull; uncontrollable twitching, jerking or writhing movements,</p><p>&bull; trembling,</p><p>&bull; headache,</p><p>&bull; tiredness,</p><p>&bull; sleepiness,</p><p>&bull; light-headedness,</p><p>&bull; shaking and blurred vision,</p><p>&bull; decreased number of or difficulty making bowel movements,</p><p>&bull; indigestion,</p><p>&bull; feeling sick,</p><p>&bull; more saliva in mouth than normal,</p><p>&bull; vomiting,</p><p>&bull; feeling tired.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><p>&bull; increased blood levels of the hormone prolactin,</p><p>&bull; too much sugar in the blood,</p><p>&bull; depression,</p><p>&bull; altered or increased sexual interest,</p><p>&bull; uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia),</p><p>&bull; muscle disorder causing twisting movements (dystonia),</p><p>&bull; restless legs,</p><p>&bull; double vision,</p><p>&bull; eye sensitivity to light,</p><p>&bull; fast heartbeat,</p><p>&bull; a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting,</p><p>&bull; hiccups.</p><p>The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known:</p><p>&bull; low levels of white blood cells,</p><p>&bull; low levels of blood platelets,</p><p>&bull; allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),</p><p>&bull; onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,</p><p>&bull; high blood sugar,</p><p>&bull; not enough sodium in the blood,</p><p>&bull; loss of appetite (anorexia),</p><p>&bull; weight loss,</p><p>&bull; weight gain,</p><p>&bull; thoughts of suicide, suicide attempt and suicide,</p><p>&bull; feeling aggressive,</p><p>&bull; agitation,</p><p>&bull; nervousness,</p><p>&bull; combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome),</p><p>&bull; seizure,</p><p>&bull; serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),</p><p>&bull; speech disorder,</p><p>&bull; fixation of the eyeballs in one position,</p><p>&bull; sudden unexplained death,</p><p>&bull; life-threatening irregular heartbeat,</p><p>&bull; heart attack,</p><p>&bull; slower heartbeat,</p><p>&bull; blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately),</p><p>&bull; high blood pressure,</p><p>&bull; fainting,</p><p>&bull; accidental inhalation of food with risk of pneumonia (lung infection),</p><p>&bull; spasm of the muscles around the voice box,</p><p>&bull; inflammation of the pancreas,</p><p>&bull; difficulty swallowing,</p><p>&bull; diarrhoea,</p><p>&bull; abdominal discomfort,</p><p>&bull; stomach discomfort,</p><p>&bull; liver failure,</p><p>&bull; inflammation of the liver,</p><p>&bull; yellowing of the skin and white part of eyes,</p><p>&bull; reports of abnormal liver tests values,</p><p>&bull; skin rash,</p><p>&bull; skin sensitivity to light,</p><p>&bull; baldness,</p><p>&bull; excessive sweating,</p><p>&bull; serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia),</p><p>&bull; abnormal muscle breakdown which can lead to kidney problems,</p><p>&bull; muscle pain,</p><p>&bull; stiffness,</p><p>&bull; involuntary loss of urine (incontinence),</p><p>&bull; difficulty in passing urine,</p><p>&bull; withdrawal symptoms in newborn babies in case of exposure during pregnancy,</p><p>&bull; prolonged and/or painful erection,</p><p>&bull; difficulty controlling core body temperature or overheating,</p><p>&bull; chest pain,</p><p>&bull; swelling of hands, ankles or feet,</p><p>&bull; in blood tests: increased or fluctuating blood sugar, increased glycosylated haemoglobin.</p><p>&bull; Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:</p><p>- strong impulse to gamble excessively despite serious personal or family consequences</p><p>- altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive</p><p>- uncontrollable excessive shopping</p><p>- binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)</p><p>- a tendency to wander away.</p><p>Tell your doctor if you experience any of these behaviours; he/she will discuss ways of managing or reducing the symptoms.</p><p>In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In addition, cases of stroke or &quot;mini&quot; stroke have been reported.</p><p><strong>Additional side effects in children and adolescents</strong></p><p>Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (greater than 1 in 100 patients).</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any possible side effects not listed in this leaflet, please tell your doctor or pharmacist. You can also report side effects directly (see section 6). By reporting side affects you can help provide more information on the safety of this medicine.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; npc.drug@sfda.gov.sa</p><p>Website: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; https://ade.sfda.gov.sa</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use them after the expiry date that is printed on the pack after &ldquo;EXP:&rdquo;. The expiry date refers to the last day of that month.</p><p>&bull; Store below 30 &deg;C.</p><p>&bull; Store in the original package in order to protect from moisture.</p><p>&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance is aripiprazole.</strong></p><p>Each tablet contains 10 mg of aripiprazole.</p><p>Each tablet contains 15 mg of aripiprazole.</p><p><strong>The other ingredients</strong> Lactose monohydrate powder, Maize starch, Hydroxypropyl Cellulose, Pregelatinized starch, Red iron oxide (Arify 10 mg), Yellow iron oxide (Arify 15 mg) and Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Arify 10 mg tablets are Pink, rectangular shaped, uncoated tablets embossed with ′B7`on one side and plain on the other side.
side and plain on the other side.
Arify 15 mg tablets are Yellow, round shaped, uncoated tablets, embossed with ′B5` on one side and plain on the other side.
Arify tablets are available in blister packs containing 10 tablets and each box contains three blisters (30 tablets).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer </strong></p><p><strong>Alrai Pharmaceutical Industries Co. (L.L.C.)</strong></p><p>Al Wadi, Building No. 2684, Additional No. 6236</p><p>Unit No. 1, Jeddah 22518 Almu&rsquo;tasem Bellah Al Fatemy Street</p><p>P.O.Box: 9224 Jeddah - 21413 Kingdom of Saudi Arabia</p><p><u>Tel</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966 12 2888949</p><p><u>E-mail:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; info@alraipharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 12/2022, Revision 0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص أريفاي على المادة الفعالة أريبيبرازول التي تنتمي إلى مجموعة من الأدوية تسمى مضادات الذهان، وتستخدم في علاج البالغين والمراهقين الذين تبلغ أعمارهم 15 عامًا فأكثر ويعانون من مرض يتصف بالأعراض الآتية: سماع، رؤية أو الإحساس بأشياء غير موجودة في الواقع، الشك، معتقدات خاطئة، كلام غير مترابط و اضطراب السلوك و المشاعر. قد يشعر الأشخاص الذين يعانون من هذه الحالة أيضاً بالاكتئاب، إحساس بالذنب، قلق أو توتر.</p><p>يستخدم أريفاي لعلاج البالغين والمراهقين الذين تبلغ أعمارهم 13 عامًا فما فوق ويعانون من حالة تتمثل أعراضها بشعور مفرط بالسعادة، الشعور بامتلاك طاقة كبيرة، عدم الحاجة إلى النوم كما في المعتاد، التحدث بسرعة كبيرة مع اضطراب الأفكار و في بعض الأحيان شعور حاد بالغضب. و يستخدم أيضاً عند البالغين لمنع ظهور هذه الحالة مرة أخرى عند المرضى الذين استجابوا للعلاج بـ أريفاي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أريفاي </strong></p><p dir="RTL">&bull; إذا كان لديك حساسية من &nbsp;أريبيبرازول أو لأي من المكونات الأخرى المستخدمة في هذا الدواء (انظر القسم 6).</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث الى طبيبك قبل تناول أريفاي</p><p dir="RTL">تم الإبلاغ عن أفكار وسلوكيات انتحارية خلال فترة العلاج بدواء أريبيبرازول. أخبر طبيبك على الفور إذا كان لديك أي أفكار أو مشاعر حول إيذاء نفسك.</p><p dir="RTL">تحدث الى طبيبك قبل تناول أقراص أريفاي<strong> </strong>إذا كنت تعاني من</p><p dir="RTL">&bull; ارتفاع نسبة السكر في الدم (تصاحبه أعراض مثل: العطش الشديد، تكرار الحاجة إلى التبول، وزيادة الشهية، والشعور بالضعف)، أو إذا كان لديك تاريخ عائلي بالإصابة بمرض السكري.</p><p dir="RTL">&bull; نوبات تشنجية (صرع)، قد يرغب طبيبك ان يراقب حالتك بعناية</p><p dir="RTL">&bull; حركات عضلية لا إرادية غير منتظمة، وخاصة في الوجه.</p><p dir="RTL">&bull; أمراض قلبية وعائية، إذا سبق و عانى أحد أفراد العائلة من أمراض قلبية وعائية، سكتة دماغية بما في ذلك تلك التي لا تستمر لفترة طويلة، اضطراب ضغط الدم.</p><p dir="RTL">&bull; جلطات الدم، أو إذا سبق و عانى أحد أفراد العائلة من جلطات الدم، حيث أن مضادات الذهان مرتبطة بتكون جلطات الدم.</p><p dir="RTL">&bull; الإصابة من قبل بمرض القمار المفرط.</p><p dir="RTL">إذا لاحظت زيادة في الوزن، حدوث حركات لا إرادية، أو تشعر بنعاس شديد يتعارض مع الأنشطة اليومية الاعتيادية، أو شعرت بعصوبة في التنفس أو أعراض حساسية، فأخبر طبيبك.</p><p dir="RTL">إذا كنت من المرضى كبار السن وتعاني من الخرف (فقدان الذاكرة والقدرات العقلية الأخرى)، يجب عليك أنت أو القائم على رعايتك/أحد أقاربك إخبار الطبيب إذا كنت قد اُصبت من قبل بسكتة دماغية بما في ذلك تلك التي لم تستمر لفترة طويلة.</p><p dir="RTL">أخبر طبيبك على الفور إذا كان ينتابك أي أفكار أو مشاعر عن إيذاء نفسك. لقد تم الإبلاغ عن حالات حصل لديها الرغبة بالانتحار خلال فترة العلاج بـ أريبيبرازول.</p><p dir="RTL">أخبر طبيبك على الفور إذا كنت تعاني من عدم مرونة أو تصلب في العضلات مصحوبه بحرارة مرتفعة، تعرق، حالة عقلية متغيرة، أو ضربات قلب سريعة أو غير منتظمة.</p><p dir="RTL">أخبر طبيبك إذا لاحظت انت أو القائم على رعايتك/أحد اقاربك أنك تقوم بدوافع أو اشتهاء التصرف بطرق غير معتادة بالنسبة لك ولا يمكنك مقاومة هذا الدافع، الدافع للقيام بأنشطة معينة يمكن أن تؤذي نفسك أو الآخرين.</p><p dir="RTL">وتسمى هذه اضطرابات السيطرة على الانفعالات ويمكن أن تشمل سلوكيات مثل إدمان القمار، الأكل أو الانفاق المفرط، الدافع الجنسي العالي بشكل غير طبيعي أو الانشغال بزيادة الأفكار أو المشاعر الجنسية.</p><p dir="RTL"><u>قد يحتاج طبيبك إلى تعديل أو إيقاف جرعتك. </u></p><p dir="RTL">قد يسبب اريبيبرازول النعاس، انخفاض ضغط الدم عند الوقوف، دوخة وتغيرات في قدرتك على الحركة والتوازن، مما قد يؤدي إلى السقوط. يجب الحذر، خاصة إذا كنت مريضًا مسناً أو تعاني من الضعف.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">تجنب إعطاء الأطفال والمراهقين اقل من 13 عاماً هذا الدواء؛ نظراً لعدم التأكد من كون هذا الدواء آمنا وفعالاً لإعطائه لهؤلاء المرضى.</p><p dir="RTL">التداخلات الدوائية من تناول أريفاي مع أي أدوية أخرى أو أعشاب أو مكملات &nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، وتشمل الأدوية التي اشتريتها دون وصفة طبية.</p><p dir="RTL">الأدوية الخافضة لضغط الدم: قد يزيد أريفاي<strong> </strong>من تأثير الأدوية المستخدمة لخفض ضغط الدم. تأكد من إخبار طبيبك إذا كنت تتناول دواء لضبط مستوى ضغط الدم.<strong> </strong></p><p dir="RTL">قد يؤدي تناول أقراص أريفاي<strong> </strong>مع بعض الأدوية إلى ضرورة تغيير جرعتك أو الأدوية الأخرى. من المهم أن تذكر لطبيبك الأدوية التالية:<strong> </strong></p><p dir="RTL">&bull; أدوية تنظيم ضربات القلب (مثل كينيدين، أميودارون، فليكاينيد).</p><p dir="RTL">&bull; مضادات الاكتئاب، أو العلاجات العشبية المستخدمة لعلاج الاكتئاب والقلق (مثل فلوكستين، باروكستين، فينلافاكسين، نبتة سانت جون).</p><p dir="RTL">&bull; مضادات الفطريات (مثل كيتوكونازول، إيتراكونازول).</p><p dir="RTL">&bull; بعض الأدوية المتخصصة في علاج عدوى فيروس نقص المناعة المكتسبة (مثل إيفافيرينز، نيفيرابين، مثبطات الأنزيم البروتيني مثل إندينافير، ريتونافير)</p><p dir="RTL">&bull; مضادات التشنج التي تستخدم لعلاج الصرع ( مثل كاربامازيبين، الفينيتوين، الفينوباربيتال)</p><p dir="RTL">&bull; بعض المضادات الحيوية المستخدمة في علاج مرض السل (ريفابوتين، ريفامبيسين).</p><p dir="RTL">هذه الأدوية قد تزيد من خطر الآثار الجانبية أو تقلل من تأثير أريفاي؛ إذا ظهرت لديك أي أعراض غير اعتيادية أثناء تناول أي من هذه الادوية مع أريفاي، يجب أن تُخبر طبيبك.</p><p dir="RTL">عادةً ما تستخدم الأدوية التي تزيد من مستوى السيروتونين في حالات تشمل الاكتئاب واضطراب القلق العام واضطراب الوسواس القهري والرهاب الاجتماعي وكذلك الصداع النصفي والألم:</p><p dir="RTL">&bull; أدوية التريبتان والترامادول والتريبتوفان المستخدمة في حالات تشمل الاكتئاب واضطراب القلق العام واضطراب الوسواس القهري والرهاب الاجتماعي وكذلك الصداع النصفي والألم</p><p dir="RTL">&bull; مثبطات امتصاص السيروتونين الانتقائية (مثل باروكستين وفلوكستين) المستخدمة للاكتئاب والوسواس القهري والذعر والقلق.</p><p dir="RTL">&bull; مضادات الاكتئاب الأخرى (مثل فينلافاكسين وتريبتوفان) المستخدمة في حالات الاكتئاب الشديد.</p><p dir="RTL">&bull; مضاد اكتئاب ثلاثي الحلقات (مثل كلوميبرامين وأميتريبتيلين) المستخدمة لمرض الاكتئاب</p><p dir="RTL">&bull; نبتة سانت جون (العرن المثقوب) التي تستخدم كعلاج عشبي للاكتئاب الخفيف.</p><p dir="RTL">&bull; مسكنات الآلام ( مثل ترامادول وبيثيدين) المستخدمة لتسكين الآلام</p><p dir="RTL">&bull; أدوية التريبتان (مثل يوماتريبتان وزولميتريبتان) المستخدمة في علاج الصداع النصفي.</p><p dir="RTL">قد تزيد هذه الأدوية من خطر الآثار الجانبية. إذا ظهرت لديك أي أعراض غير اعتيادية أثناء تناول أي من هذه الأدوية مع أريفاي، يجب أن تتحدث الى طبيبك.</p><p dir="RTL"><strong>تناول أريفاي مع الطعام والشراب والكحول:</strong></p><p dir="RTL">يمكن تناول هذا الدواء مع الطعام أو بدونه.</p><p dir="RTL">يجب تجنب تناول الكحول أثناء فترة تناول أريفاي.</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة </strong></p><p dir="RTL">إذا كنتِ حامل أو مرضع أو تعتقدين أنك حامل أو تخططين للحمل، استشيري طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">يمكن أن تحدث الأعراض التالية عند الأطفال حديثي الولادة، الذين ولدوا لأمهات استعملن أريفاي خلال الشهور الثلاث الأخيرة من الحمل: رعاش، تصلب و/أو ضعف العضلات، شعور بالنعاس، سرعة انفعال، مشاكل في التنفس، و صعوبة الإرضاع. إذا اصيب طفلك بأي من هذه الأعراض يجب الاتصال بالطبيب.</p><p dir="RTL">إذا كنتِ تتناولين أريفاي<strong>، </strong>فسوف يناقش طبيبك معك ما إذا كان يجب عليك الرضاعة الطبيعية مع الأخذ في الاعتبار الفائدة التي تعود عليكِ من علاجك والفائدة التي تعود على طفلك من الرضاعة الطبيعية. يجب عدم الرضاعة وتناول أريفاي معاً</p><p dir="RTL">تحدثي إلى طبيبك حول أفضل طريقة لإطعام طفلك إذا كنتِ تتناولين هذا الدواء.</p><p dir="RTL"><strong>تأثير أريفاي على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تحدث دوخة و مشاكل في الرؤية أثناء العلاج بهذا الدواء (انظر القسم 4).</p><p dir="RTL">يجب أخذ ذلك في الاعتبار في الحالات التي تتطلب الانتباه الكامل، على سبيل المثال عند قيادة السيارة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول هذا الدواء تماما كما أخبرك به الطبيب أو الصيدلي إن لم تكن متأكداً من كيفية الاستخدام ارجع إلى طبيبك أو الصيدلي.</p><p dir="RTL"><strong>الجرعة الموصى بها للبالغين</strong><strong> </strong><strong>هي 15 ملجم مرة واحدة يومياً. </strong>بالرغم من ذلك، قد يصف لك طبيبك جرعة أقل أو أكبر بحيث لا تزيد على 30 ملجم مرة واحدة يومياً.</p><p dir="RTL"><strong>الاستخدام من قبل الأطفال والمراهقين</strong></p><p dir="RTL">قد تبدأ تناول هذا المنتج الدوائي بجرعة منخفضة في شكل محلول (سائل) يؤخذ عن طريق الفم.</p><p dir="RTL">قد يزيد طبيبك الجرعة تدريجياً حتى تصل إلى <strong>الجرعة الموصى بها للمراهقين والتي تبلغ 10 ملجم مرة واحدة يومياً.</strong> بالرغم من ذلك، قد يصف لك طبيبك جرعة أقل أو أكبر بحيث لا تزيد على 30 ملجم مرة واحدة يومياً.</p><p dir="RTL">إذا شعرت أن تأثير أقراص أريفاي<strong> </strong>قوي جداً أو ضعيف جداً فاستشر الطبيب أو الصيدلي.<strong> </strong></p><p dir="RTL"><strong>حاول أن تتناول جرعتك اليومية من أقراص أريفاي في نفس الوقت كل يوم. </strong>يمكن تناول الأقراص مع الطعام أو بدونه. تناول القرص دائماً مع الماء وابتلعه كاملاً.</p><p dir="RTL"><strong>حتى وإن كنت تشعر بتحسن، </strong>لا تقوم بتغيير الجرعة اليومية من أقراص<strong> </strong>أريفاي أو إيقافها دون استشارة طبيبك أولاً.</p><p dir="RTL"><strong>إذا تناولت أريفاي أكثر من اللازم</strong></p><p dir="RTL">إذا أدركت أنك قد تناولت أريفاي أكثر مما أوصى به طبيبك (أو إذا أخذ شخص آخر بعضاً من أريفاي الخاص بك)، اتصل بطبيبك على الفور. إذا لم تتمكن من الوصول إلى طبيبك، فانتقل إلى أقرب مستشفى وخذ العلبة معك.</p><p dir="RTL">عانى المرضى الذين تناولوا الكثير من أريبيبرازول من الأعراض التالية:</p><p dir="RTL">&bull; سرعة ضربات القلب، الغضب / العدوانية، ومشاكل في الكلام.</p><p dir="RTL">&bull; حركات غير عادية (خاصة للوجه أو اللسان) وانخفاض مستوى الوعي.</p><p dir="RTL">أعراض اخرى، تشمل:</p><p dir="RTL">&bull; ارتباك حاد، نوبات (صرع)، غيبوبة، مزيج من الحمى، سرعة في التنفس، تعرق.</p><p dir="RTL">&bull; تصلب العضلات، والنعاس، وبطء التنفس، والاختناق، وارتفاع أو انخفاض ضغط الدم، وعدم انتظام ضربات القلب.</p><p dir="RTL">اتصل بطبيبك أو المستشفى على الفور إذا واجهت أيًا مما سبق.</p><p dir="RTL"><strong>إذا نسيت أن تتناول أريفاي</strong></p><p dir="RTL">إذا نسيت تناول جرعة، قم بتناولها حال تذكرك ولكن لا تتناول جرعتين في يوم واحد.</p><p dir="RTL"><strong>إذا توقفت عن تناول أريفاي</strong></p><p dir="RTL">لا تتوقف عن علاجك لمجرد أنك شعرت بتحسن. من المهم أن تستمر في تناول أقراص أريفاي<strong> </strong>طالما أخبرك طبيبك بذلك.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، أسال طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع كل الأدوية هذا الدواء يمكن أن يتسبب بأعراض جانبية. بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL"><strong>شائع (قد يؤثر على شخص من كل 10 أشخاص):</strong></p><p dir="RTL">&bull; السكري،</p><p dir="RTL">&bull; صعوبة النوم،</p><p dir="RTL">&bull; الشعور بالقلق،</p><p dir="RTL">&bull; الشعور بالضيق وعدم القدرة على الاحتفاظ بالهدوء، صعوبة في الجلوس هادئاً،</p><p dir="RTL">&bull; الإصابة بداء تعذر الجلوس (شعور غير مريح بالتململ الداخلي والحاجة الملحة للتحرك باستمرار)،</p><p dir="RTL">&bull; حركات غير قابلة للسيطرة مثل، الوخز، الاهتزاز، الالتواء</p><p dir="RTL">&bull; الارتعاش،</p><p dir="RTL">&bull; الصداع،</p><p dir="RTL">&bull; التعب،</p><p dir="RTL">&bull; الشعور بالنعاس،</p><p dir="RTL">&bull; الدوخة،</p><p dir="RTL">&bull; الارتعاش ورؤية ضبابية،</p><p dir="RTL">&bull; انخفاض حركة الأمعاء أو صعوبة حركتها،</p><p dir="RTL">&bull; عسر الهضم،</p><p dir="RTL">&bull; الشعور بالغثيان،</p><p dir="RTL">&bull; زيادة إفراز اللعاب داخل الفم أكثر من المعتاد،</p><p dir="RTL">&bull; القيء،</p><p dir="RTL">&bull; الشعور بالتعب.</p><p dir="RTL"><strong>غير شائع (قد يؤثر على شخص من كل 100 شخص):</strong></p><p dir="RTL">&nbsp;&bull;زيادة مستويات هرمون البرولاكتين في الدم،</p><p dir="RTL">&nbsp;&bull;ارتفاع مستوى السكر في الدم،</p><p dir="RTL">&nbsp;&bull;الاكتئاب،</p><p dir="RTL">&bull; تغير في الرغبة الجنسية أو زيادتها،</p><p dir="RTL">&bull; حركة لا إرادية للفم واللسان والأطراف (خلل الحركة المتأخر)،</p><p dir="RTL">&bull; اضطراب العضلات المسبب لحركات التوائية (خلل التوتر)،</p><p dir="RTL">&bull; الرؤية المزدوجة،</p><p dir="RTL">&bull; زيادة سرعة ضربات القلب،</p><p dir="RTL">&bull; انخفاض في ضغط الدم عند الوقوف مما يسبب الشعور بالدوار، أو الدوخة، أو الإغماء،</p><p dir="RTL">&bull; حازوقة.</p><p dir="RTL">تمت الإفادة بحدوث الأعراض الجانبية الآتي ذكرها منذ بداية تسويق هذا الدواء ولكن ليست لدينا أية تقديرات لاحتمالية تكرار حدوث هذه الأعراض بين المرضى حتى الآن:</p><p dir="RTL">&bull; نقص عدد كرات الدم البيضاء،</p><p dir="RTL">&bull; نقص عدد الصفائح الدموية،</p><p dir="RTL">&bull; رد فعل تحسسي (مثل: تورم الفم واللسان والوجه والحلق، أو الطفح الجلدي والشعور بالحكّة)،</p><p dir="RTL">&bull; الإصابة بمرض السكري أو التدهور في الحالة، أو الحماض الكيتوني السكري (وجود الكيتونات في الدم والبول)، أو الغيبوبة،</p><p dir="RTL">&bull; ارتفاع نسبة الكسر في الدم،</p><p dir="RTL">&bull; انخفاض نسبة الصوديوم في الدم،</p><p dir="RTL">&bull; فقدان الشهية (قلة الشهية للطعام)،</p><p dir="RTL">&bull; فقدان الوزن،</p><p dir="RTL">&bull; زيادة الوزن،</p><p dir="RTL">&bull; أفكار انتحارية، محاولة الانتحار أو الانتحار،</p><p dir="RTL">&bull; السلوك العدواني،</p><p dir="RTL">&bull; التهيج العصبي،</p><p dir="RTL">&bull; الاندفاع العصبي،</p><p dir="RTL">&bull; مجموعة من الآثار الجانبية مثل الحمى، وتيبس العضلات، ومعدل التنفس السريع، والتعرق، وقلة الإدراك، وتغيرات مفاجئة في ضغط الدم، ومعدل ضربات القلب، والإغماء (متلازمة مضادات الذهان الخبيثة)،</p><p dir="RTL">&bull; النوبات التشنجية،</p><p dir="RTL">&bull; متلازمة السيروتونين (تفاعل قد يؤدي إلى الشعور بالسعادة الغامرة، أو الدوار، أو الخرف، أو التململ، أو الشعور بالثمل، الحمى، أو التعرق، أو تيبس العضلات)،</p><p dir="RTL">&bull; اضطراب الكلام،</p><p dir="RTL">&bull; تثبيت العين في موضع واحد،</p><p dir="RTL">&bull; موت مفاجئ غير محدد السبب،</p><p dir="RTL">&bull; ضربات قلب غير منتظمة مهددة للحياة،</p><p dir="RTL">&bull; الأزمة القلبية،</p><p dir="RTL">&bull; انخفاض في معدل ضربات القلب،</p><p dir="RTL">&bull; جلطات دموية في الأوردة وخاصة في الساقين (وتشمل الاعراض تورم الساق واحمرارها، والشعور بألم فيها)، والتي قد تنتقل خلال الأوعية الدموية ومنها إلى الرئتين مسببة ألماً في الصدر وصعوبة في التنفس (إذا لاحظت أي من هذه الأعراض فاحصل على الاستشارة الطبية على الفور)،</p><p dir="RTL">&bull; ارتفاع ضغط الدم،</p><p dir="RTL">&bull; الإغماء،</p><p dir="RTL">&bull; دخول الطعام في مجرى الهواء عن طريق الخطأ مع احتمال الإصابة بالتهاب رئوي،</p><p dir="RTL">&bull; تقلص العضلات المحيطة بالحنجرة،</p><p dir="RTL">&bull; التهاب البنكرياس،</p><p dir="RTL">&bull; صعوبة البلع،</p><p dir="RTL">&bull; الاسهال،</p><p dir="RTL">&bull; الشعور بعدم الارتياح في البطن،</p><p dir="RTL">&bull; الشعور بعدم الارتياح في المعدة،</p><p dir="RTL">&bull; فشل الكبد،</p><p dir="RTL">&bull; التهاب الكبد،</p><p dir="RTL">&bull; اصفرار الجلد وبياض العين (يرقان)،</p><p dir="RTL">&bull; قيم غير طبيعية في فحوص الكبد،</p><p dir="RTL">&bull; الطفح الجلدي،</p><p dir="RTL">&bull; الحساسية للضوء،</p><p dir="RTL">&bull; الصلع،</p><p dir="RTL">&bull; فرط التعرق،</p><p dir="RTL">&bull; تفاعلات حساسية خطيرة مثل متلازمة فرط الحساسية المحرض بالأدوية (DRESS). يظهر هذا التفاعل في البداية على شكل أعراض شبيهة بالأنفلونزا مع ظهور طفح جلدي على الوجه ثم مع طفح جلدي ممتد ودرجة حرارة وتضخم في الغدد الليمفاوية وزيادة مستويات إنزيمات الكبد التي تظهر في اختبارات الدم وزيادة في نوع من خلايا الدم البيضاء (ايزوفيليا)،</p><p dir="RTL">&bull; تحلل غير طبيعي في العضلات مما قد يؤدي إلى مشاكل في الكلى،</p><p dir="RTL">&bull; ألم في العضلات،</p><p dir="RTL">&bull; تيبس العضلات،</p><p dir="RTL">&bull; فقدان التحكم الإرادي في التبول (سلس البول)،</p><p dir="RTL">&bull; صعوبة في التبول،</p><p dir="RTL">&bull; ظهور أعراض الانسحاب في الأطفال حديثي الولادة الذين تعرضوا للدواء أثناء فترة الحمل،</p><p dir="RTL">&bull; انتصاب مُطوّل و/أو مؤلم،</p><p dir="RTL">&bull; صعوبة في التحكم في درجة حرارة الجسم الداخلية أو فرط السخونة،</p><p dir="RTL">&bull; الم في الصدر،</p><p dir="RTL">&bull; تورم اليدين، الكاحلين أو القدمين،</p><p dir="RTL">&bull; في اختبارات الدم: عدم انتظام مستوى السكر في الدم وزيادة الهيموجلوبين السكري،</p><p dir="RTL">&bull; عدم القدرة على مقاومة الاندفاع، أو الدافع للقيام بعمل يمكن أن يضر بك أو بالآخرين، والذي قد يشمل:</p><p dir="RTL">- دافع قوي للمقامرة بشكل مفرط على الرغم من العواقب الشخصية أو العائلية الخطيرة.</p><p dir="RTL">- تغيير أو زيادة الاهتمام الجنسي والسلوك الذي يثير قلقًا كبيرًا لك أو للآخرين، على سبيل المثال، الدافع الجنسي المتزايد.</p><p dir="RTL">- فرط التسوق (الشراء) مع عدم القدرة على التحكم فيه.</p><p dir="RTL">- الاكل بشراهة (تناول كميات كبيرة من الطعام في فترة زمنية قصيرة) أو النّهم المرضي للأكل (تناول طعام أكثر من المعتاد وأكثر مما هو مطلوب لإشباع جوعك).</p><p dir="RTL">- الميل الى الشرود بعيدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا واجهت أيًا من هذه السلوكيات؛ سيناقش / ستناقش طرق إدارة أو تقليل الأعراض.</p><p dir="RTL">في المرضى كبار السن المصابين بالخرف، تم الإبلاغ عن عدد أكبر من حالات الوفاة خلال فترة العلاج باريبيبرازول</p><p dir="RTL">كما تم الإبلاغ عن حدوث حالات سكتة دماغية أو جلطات دماغية صغيرة.</p><p dir="RTL"><strong>الآثار الجانبية الإضافية لدى الأطفال والمراهقين </strong></p><p dir="RTL">ظهر على المراهقين الذين يبلغون 13 عاماً فأكثر آثار جانبية مشابهة لتلك الآثار الجانبية التي تظهر لدى البالغين من حيث معدل التكرار والنوع باستثناء الشعور بالنعاس، والتشنجات، أو الاهتزازات العضلية اللاإرادية، والتململ، والشعور بالتعب والتي كانت شديدة الشيوع (أكثر من مريض واحد من كل 10 مرضى) والشعور بألم في اعلى البطن، وجفاف الفم، وزيادة معدل ضربات القلب، وزيادة الوزن، وزيادة الشهية، واهتزاز العضلات، وحركات الأطراف اللاإرادية، والشعور بالدوار، وخاصة عند النهوض من وضع الاستلقاء أو وضع الجلوس من الآثار الجانبية الشائعة (أكثر من مريض واحد من كل 100 مريض)</p><p dir="RTL"><strong>التبليغ عن الأعراض الجانبية</strong></p><p dir="RTL">في حال زادت الأعراض الجانبية سوءً أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، قم بالتواصل مع الطبيب أو الصيدلي. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً (انظر القسم 6). عن طريق الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد :&nbsp;&nbsp; &nbsp;19999</p><p dir="RTL">البريد الإلكتروني:&nbsp;&nbsp; &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull;</strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يحفظ أريفاي بعيدًا عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدمها بعد تاريخ انتهاء الصلاحية المطبوع على العبوة بعد &quot;EXP:&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يحفظ في درجة حرارة أقل من 30 &deg;م.</p><p dir="RTL">&bull; يخزن في العلبة الأصلية من أجل الحماية من الرطوبة.</p><p dir="RTL">&bull; يجب عدم التخلص من الأدوية في مياه الصرف أو مع مخلفات المنزل. أسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي أريبيبرازول</strong></p><p dir="RTL">كل قرص يحتوي على 10 ملجم أريبيبرازول</p><p dir="RTL">كل قرص يحتوي على 15 ملجم أريبيبرازول</p><p dir="RTL"><strong>المكونات الأخرى هي</strong> لاكتوز أحادي الهيدرات، نشا الذرة، هيدروكسي بروبيل السليلوز، نشا بريجيلاتنايزد، أكسيد الحديد الأحمر) أريفاي 10 ملجم)، أكسيد الحديد الأصفر(أريفاي 15 ملجم)، وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو الشكل الصيدلاني لـ أريفاي وماهي محتويات العلبة</strong></p><p dir="RTL"><strong><u>أريفاي</u></strong><u> 10ملجم</u> عبارة عن أقراص وردية، مستطيلة الشكل غير مغلفة محفور عليها علامة (B7) على جانب واحد.</p><p dir="RTL"><strong><u>أريفاي</u></strong><u> 15 ملجم</u> عبارة عن أقراص صفراء، مستديرة الشكل ثنائية التحدب غير مغلفة محفور عليها (B5) على جانب واحد.</p><p dir="RTL">تتوفر <strong>أقراص أريفاي</strong> في شريط يحتوي على 10 أقراص وتحتوي كل علبة على ثلاث أشرطة (30 قرص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة</strong><strong> </strong><strong>مصنع</strong><strong> </strong><strong>الرأي</strong><strong> </strong><strong>للصناعات</strong><strong> </strong><strong>الدوائية(</strong><strong>ذ</strong><strong>.</strong><strong>م</strong><strong>.</strong><strong>م</strong><strong>.)</strong></p><p dir="RTL">الوادي، مبنى رقم 2684 ، الرقم الإضافي 6236 ، وحدة رقم 1</p><p dir="RTL">جدة 22518 شارع المعتصم بالله الفاطمي.</p><p dir="RTL">صندوق بريد: 9224 جدة - ٢١٤١٣ المملكة العربية السعودية</p><p dir="RTL">تلفون:&nbsp; &nbsp; 122888949 966+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL">ايميل:&nbsp; Info@alraipharma.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة في 2022/12، نسخة رقم 0 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arify 10 mg Tablets
Arify 15 mg Tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 mg: Each tablet contains 10 mg of aripiprazole. 
Excipient with known effect
51.95 mg lactose (as monohydrate) per tablet
15 mg: Each tablet contains 15 mg of aripiprazole.
Excipient with known effect
77.65 mg lactose (as monohydrate) per tablet
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet 
10 mg: pink, rectangular shaped, uncoated tablets embossed with "B7" on one side and plain on the other side.
15 mg: yellow, round shaped, uncoated tablets embossed with "B5" on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal is for diagnostic use only.</p><p>ARIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.</p><p>ARIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</p><p>ARIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em><u>Adults </u></em></p><p><em>Schizophrenia:</em> the recommended starting dose for ARIFY is 10 mg/day or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ARIFY is effective in a dose range of 10 mg/day to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p><em>Manic episodes in Bipolar I Disorder:</em> the recommended starting dose for ARIFY is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p>Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</p><p><em><u>Paediatric population</u></em></p><p><em>Schizophrenia in adolescents aged 15 years and older:</em> the recommended dose for ARIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ARIFY oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1). ARIFY is effective in a dose range of 10 mg/day to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose. ARIFY is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</p><p><em>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older:</em> the recommended dose for ARIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ARIFY oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ARIFY is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</p><p><em>Irritability associated with autistic disorder:</em> the safety and efficacy of ARIFY in children and adolescents aged below 18 years have not yet been established. Currently available data are described 3 in section 5.1 but no recommendation on a posology can be made.</p><p>Tics associated with Tourette&rsquo;s disorder: the safety and efficacy of ARIFY in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><em><u>Special population</u></em></p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required in patients with renal impairment.</p><p><em>Elderly</em></p><p>The safety and efficacy of ARIFY in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</p><p><em>Gender</em></p><p>No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</p><p><em>Smoking status</em></p><p>According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).</p><p><em>Dose adjustments due to interactions</em></p><p>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5). When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</p><p><u>Method of administration</u></p><p>Precautions to be taken</p><p>ARIFY is for oral use.</p><p>Orodispersible tablets or oral solution may be used as an alternative to ARIFY tablets for patients who have difficulty swallowing ARIFY tablets (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</p><p><u>Suicidality</u></p><p>The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in 4 some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic treatment.</p><p><u>Cardiovascular disorders</u></p><p>Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.</p><p><u>QT prolongation </u></p><p>In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</p><p><u>Tardive dyskinesia</u></p><p>In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</p><p><u>Other extrapyramidal symptoms</u></p><p>In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</p><p><u>Neuroleptic Malignant Syndrome (NMS)</u></p><p>NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</p><p><u>Seizure</u></p><p>In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</p><p><u>Elderly patients with dementia-related psychosis</u></p><p><em>Increased mortality</em></p><p>&nbsp;In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 to 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer&#39;s disease, patients treated with 5 aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazoletreated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</p><p><em>Cerebrovascular adverse reactions</em></p><p>In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78 to 88 years). Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</p><p>Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</p><p><u>Weight gain</u></p><p>Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</p><p><u>Dysphagia</u></p><p>Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</p><p>Pathological gambling and other impulse control disorders</p><p>Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or 6 increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</p><p><u>Lactose</u></p><p>ARIFY tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>Patients with attention deficit hyperactivity disorder (ADHD) comorbidity Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</p><p><u>Falls</u></p><p>Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its &alpha;1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</p><p>Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</p><p>If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</p><p><u>Potential for other medicinal products to affect aripiprazole</u></p><p>A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</p><p><em>Quinidine and other CYP2D6 inhibitors</em></p><p>In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</p><p><em>Ketoconazole and other CYP3A4 inhibitors </em></p><p>In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydroaripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of 7 ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</p><p><em>Carbamazepine and other CYP3A4 inducers</em></p><p>Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John&#39;s Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose.</p><p><em>Valproate and lithium</em></p><p>When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole.</p><p><u>Potential for aripiprazole to affect other medicinal products</u></p><p>In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</p><p>When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</p><p><em>Serotonin syndrome</em></p><p>Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the 8 expected benefit clearly justifies the potential risk to the foetus.</p><p>Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).</p><p><u>Breast-feeding</u></p><p>Aripiprazole/metabolites are excreted in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from aripiprazole therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.</p><p><u>Tabulated list of adverse reactions</u></p><p>The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or postmarketing use.</p><p>All ADRs are listed by system organ class and frequency; very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;.</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and</strong></p><p><strong>lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Neutropenia Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus allergic, or</p><p>urticaria)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperprolactinaemia Blood prolactin</p><p>decreased</p></td><td style="vertical-align:top"><p>Diabetic hyperosmolar coma Diabetic ketoacidosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and</strong></p><p><strong>nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Diabetes mellitus</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Hyponatremia</p><p>Anorexia</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia Anxiety Restlessness</p></td><td style="vertical-align:top"><p>Depression Hypersexuality</p></td><td style="vertical-align:top"><p>Suicide attempt, suicidal ideation and completed suicide (see section 4.4)</p><p>Pathological gambling Impulse-control disorder Binge eating Compulsive shopping Poriomania</p><p>Aggression Agitation</p><p>&nbsp; Nervousness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Akathisia Extrapyramidal disorder Tremor Headache Sedation Somnolence</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Tardive dyskinesia Dystonia</p><p>Restless legs syndrome</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome Grand mal convulsion</p><p>Serotonin syndrome Speech disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Diplopia</p><p>Photophobia</p></td><td style="vertical-align:top"><p>Oculogyric crisis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Sudden death unexplained Torsades de pointes Ventricular arrhythmia</p><p>Cardiac arrest Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension</p><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and</strong></p><p><strong>mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hiccups</p></td><td style="vertical-align:top"><p>Aspiration pneumonia Laryngospasm Oropharyngeal spasm</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Constipation Dyspepsia Nausea Salivary hypersecretion</p><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p><p>&nbsp;&nbsp;Dysphagia</p><p>Diarrhoea</p><p>Abdominal discomfort Stomach discomfort</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic failure</p><p>Hepatitis</p><p>&nbsp;&nbsp;Jaundice</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p><p>Photosensitivity reaction Alopecia</p><p>Hyperhidrosis</p><p>Drug Reaction with Eosinophilia</p><p>and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective</strong></p><p><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Myalgia</p><p>Stiffness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary incontinence</p><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium and</strong></p><p><strong>perinatal conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong></p><p><strong>system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Temperature regulation disorder (e.g. hypothermia, pyrexia) Chest pain</p><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decreased Weight gain</p><p>Alanine Aminotransferase increased</p><p>Aspartate Aminotransferase increased</p><p>Gamma-glutamyltransferase increased</p><p>Alkaline phosphatase increased QT prolonged</p><p>Blood glucose increased Glycosylated haemoglobin increased</p><p>Blood glucose fluctuation Creatine phosphokinase increased</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em><u>Adults</u></em></p><p><em>Extrapyramidal symptoms (EPS)</em></p><p><em>Schizophrenia: </em>in a long-term 52-week controlled trial, aripiprazole-treated patients had an overall- lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long-term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</p><p><em>Manic episodes in Bipolar I Disorder: </em>in a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long-term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</p><p><em>Akathisia</em></p><p>In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</p><p><em>Dystonia</em></p><p>Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p><em>Prolactin</em></p><p>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</p><p><em>Laboratory parameters</em></p><p>Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</p><p><em>Paediatric population</em></p><p><em>Schizophrenia in adolescents aged 15 years and older</em></p><p>In a short-term placebo-controlled clinical trial involving 302 adolescents (13 to 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</p><p>Somnolence/sedation and extrapyramidal disorder were reported very commonly (&ge; 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (&ge; 1/100, &lt; 1/10). The safety profile in a 26-week open-label extension trial was similar to that observed in the short- term, placebo-controlled trial.</p><p>The safety profile of a long-term, double-blind, placebo-controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (&ge; 1/100,</p><p>&lt; 1/10).</p><p>In the pooled adolescent schizophrenia population (13 to 17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 29.5 % and 48.3 %, respectively. In the adolescent (13 to 17 years) schizophrenia population with aripiprazole exposure of 5 mg to 30 mg up to 72 months, incidence of low serum prolactin levels in females</p><p>(&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 25.6 % and 45.0 %, respectively.</p><p>In two long-term trials with adolescent (13 to 17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 37.0 % and 59.4 %, respectively.</p><p><em>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</em></p><p>The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (&ge; 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (&ge; 1/100,</p><p>&lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</p><p>The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %; 30 mg, 28.8 %; placebo, 1.7 %); and akathisia (incidences were</p><p>10 mg, 12.1 %; 30 mg, 20.3 %; placebo, 1.7 %).</p><p>Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</p><p>In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</p><p>In the paediatric bipolar population (10 to 17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) was 28.0 % and 53.3 %, respectively.</p><p>9<em>Pathological gambling and other impulse control disorders</em></p><p>Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see section 4.4).</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp; Saudi Arabia:</strong></p><p>&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp; SFDA Call Center: 19999</p><p>&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp; </strong>Other GCC States:</p><p>&nbsp;&nbsp;- Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.</p><p><u>Management of overdose</u></p><p>Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</p><p>Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<sub>max</sub> by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</p><p><u>Haemodialysis</u></p><p>Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</p><p><u>Mechanism of action</u></p><p>It has been proposed that aripiprazole&rsquo;s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5-HT<sub>1A</sub> receptors and antagonism of serotonin 5-HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <em>in vitro </em>for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors and moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2C</sub> and 5-HT<sub>7</sub>, alpha-1 adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</p><p>Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Adults</u></em></p><p><em>Schizophrenia</em></p><p>In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</p><p>Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-&Aring;sberg Depression Rating Scale (MADRS) showed a significant improvement over haloperidol.</p><p>In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and&nbsp;57% in placebo.</p><p><em>Weight gain</em></p><p>In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).</p><p><em>Lipid parameters</em></p><p>In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL).</p><p><em>Prolactin</em></p><p>Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</p><p>The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</p><p><em>Manic episodes in Bipolar I Disorder</em></p><p>In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</p><p>In one 3-week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</p><p>In two 12-week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</p><p>In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</p><p>In a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</p><p>In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores &le; 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for</p><p>12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</p><p><em><u>Paediatric population</u></em></p><p><em>Schizophrenia in adolescents</em></p><p>In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 to 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26-week open-label extension trial. In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13 to 17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. The point estimate of the hazard ratio (HR) was 0.461 (95 % confidence interval, 0.242 to 0.879) in the full population. In sub-group analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13 to 14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</p><p><em>Manic episodes in Bipolar I Disorder in children and adolescents</em></p><p>Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10 to 17 years), who met DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score  20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.</p><p>Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</p><p>The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment-interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</p><p><em>Irritability associated with autistic disorder in paediatric patients (see section 4.2)</em></p><p>Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52-week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/mL) and males (&lt; 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo- controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</p><p>Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13 to 26-week stabilisation on aripiprazole (2 mg/day to 15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17 % of patients, with tremor accounting for 6.5%.</p><p><em>Tics associated with Tourette&rsquo;s disorder in paediatric patients (see section 4.2)</em></p><p>The efficacy of aripiprazole was studied in paediatric subjects with Tourette&rsquo;s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo-controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 to 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35, for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</p><p>The efficacy of aripiprazole in paediatric subjects with Tourette&rsquo;s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in South- Korea. Patients were 6 to 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</p><p>In both of these short-term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long-term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Arify in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3 to 5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</p><p><u>Distribution</u></p><p>Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of</p><p>4.9 L/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</p><p><u>Biotransformation</u></p><p>Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <em>in vitro </em>studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</p><p><u>Elimination</u></p><p>The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</p><p>The total body clearance of aripiprazole is 0.7 mL/min/kg, which is primarily hepatic.</p><p>Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</p><p><u>Paediatric population</u></p><p>The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</p><p><u>Pharmacokinetics in special patient groups</u></p><p><em>Elderly</em></p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</p><p><em>Gender</em></p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</p><p><em>Smoking</em></p><p>Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.</p><p><em>Race</em></p><p>Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.</p><p><em>Renal impairment</em></p><p>The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</p><p><em>Hepatic impairment</em></p><p>A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</p><p>An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<sup>2</sup>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of <em>in vitro </em>solubility.</p><p>In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</p><p>Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non- genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Arify 10 mg tablets</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:321px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>S. No.</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ingredients</strong></p></td></tr><tr><td><p>1.</p></td><td><p>Lactose monohydrate</p></td></tr><tr><td><p>2.</p></td><td><p>Maize starch</p></td></tr><tr><td><p>3.</p></td><td><p>Hydroxypropyl Cellulose EF</p></td></tr><tr><td><p>4.</p></td><td><p>Pregelatinized starch</p></td></tr><tr><td><p>5.</p></td><td><p>Red iron oxide</p></td></tr><tr><td><p>6.</p></td><td><p>Magnesium Stearate</p></td></tr></tbody></table><p><strong><u>Arify 15 mg tablets</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:316px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>S. No.</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ingredients</strong></p></td></tr><tr><td><p>1.</p></td><td><p>Lactose monohydrate</p></td></tr><tr><td><p>2.</p></td><td><p>Maize starch</p></td></tr><tr><td><p>3.</p></td><td><p>Hydroxypropyl Cellulose EF</p></td></tr><tr><td><p>4.</p></td><td><p>Pregelatinized starch</p></td></tr><tr><td><p>5.</p></td><td><p>Yellow iron oxide</p></td></tr><tr><td><p>6.</p></td><td><p>Magnesium Stearate</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Store below 30 &deg;C.</p><p>- Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>10 mg: </strong>Arify 10 mg tablets are available in blister packs containing 10 tablets and each box contains three blisters (30 tablets).</p><p><strong>15 mg: </strong>Arify 15 mg tablets are available in blister packs containing 10 tablets and each box contains three blisters (30 tablets).</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrai Pharmaceutical Industries Co. (L.L.C.)
Al Wadi, Building No. 2684, Additional No. 6236 
Unit No. 1, Jeddah 22518 Almu'tasem Bellah Al Fatemy Street 
P.O.Box : 9224, Postal code 21413. Kingdom of Saudi Arabia 
Tel: +966 12 2888949 
E-mail: info@alraipharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>